AstraZeneca rocked by shareholder revolt over executive pay

More than 37% of shareholders vote against or abstain on vote including £9.4m pay package for pharmaceutical firm’s boss

AstraZeneca has been rocked by one of the biggest shareholder revolts over executive pay this year, after more than a third of investors failed to back the pharmaceutical company’s remuneration report.

More than 37% of shareholders voted against or abstained at the company’s annual shareholder meeting in London on Friday in the second rebuke by investors for the company in as many years.

Continue reading…

Read full original article »